ITCIUnknown
Intra-Cellular Therapies, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Intra-Cellular Therapies, Inc. (ITCI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ITCI insiders buying or selling?
Intra-Cellular Therapies, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 152 Form 4 filings for ITCI: 11 buys ($11.5M) and 141 sells ($202.6M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Dec 6, 2024)
Total Form 4 filings
152
SEC EDGAR
Insider filers
13
Insider buys (11)
$11.5M
Insider sells (141)
$202.6M
Insider sentiment
Net sellingNet insider flow of $191.0M in net selling since January 2018.
Recent ITCI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 6, 2024 | Sharon Mates | Chairman and CEO | Sale | 102.7K | $84.93 | $8.7M | SEC ↗ |
| Nov 14, 2024 | Michael Halstead | President | Sale | 41.6K | $88.79 | $3.7M | SEC ↗ |
| Aug 30, 2024 | Sharon Mates | Chairman and CEO | Sale | 70.0K | $72.70 | $5.1M | SEC ↗ |
| Aug 28, 2024 | Sharon Mates | Chairman and CEO | Sale | 95.9K | $73.54 | $7.1M | SEC ↗ |
| Aug 23, 2024 | Sharon Mates | Chairman and CEO | Sale | 121.1K | $75.05 | $9.1M | SEC ↗ |
| Aug 20, 2024 | Mark Neumann | EVP, Chief Commercial Officer | Sale | 18.7K | $75.08 | $1.4M | SEC ↗ |
| Jun 25, 2024 | RIGGS RORY B | Director | Sale | 4.5K | $75.57 | $337.2K | SEC ↗ |
| Jun 21, 2024 | Nostrand Robert L Van | Director | Sale | 20.0K | $75.91 | $1.5M | SEC ↗ |
| Mar 12, 2024 | Sharon Mates | Chairman, President & CEO | Sale | 61.3K | $66.07 | $4.0M | SEC ↗ |
| Mar 12, 2024 | Lawrence J. Hineline | SVP of Finance, CFO | Sale | 23.3K | $66.32 | $1.5M | SEC ↗ |
| Mar 12, 2024 | Michael Halstead | EVP and General Counsel | Sale | 20.5K | $66.09 | $1.4M | SEC ↗ |
| Mar 12, 2024 | Mark Neumann | EVP, Chief Commercial Officer | Sale | 20.5K | $66.23 | $1.4M | SEC ↗ |
| Mar 12, 2024 | Suresh K. Durgam | EVP, Chief Medical Officer | Sale | 10.2K | $66.21 | $672.8K | SEC ↗ |
| Feb 29, 2024 | Nostrand Robert L Van | Director | Sale | 20.0K | $72.93 | $1.5M | SEC ↗ |
| Feb 28, 2024 | Michael Halstead | EVP and General Counsel | Sale | 7.9K | $69.53 | $549.8K | SEC ↗ |
| Feb 28, 2024 | Lawrence J. Hineline | SVP of Finance, CFO | Sale | 13.3K | $69.43 | $926.0K | SEC ↗ |
| Feb 28, 2024 | Sharon Mates | Chairman, President & CEO | Sale | 22.6K | $69.79 | $1.6M | SEC ↗ |
| Feb 28, 2024 | Suresh K. Durgam | EVP, Chief Medical Officer | Sale | 4.1K | $70.17 | $288.5K | SEC ↗ |
| Feb 28, 2024 | Mark Neumann | EVP, Chief Commercial Officer | Sale | 7.9K | $70.13 | $554.5K | SEC ↗ |
| Feb 28, 2024 | Joel S Marcus | Director | Sale | 26.3K | $68.68 | $1.8M | SEC ↗ |
| Feb 5, 2024 | Michael Halstead | EVP and General Counsel | Sale | 11.9K | $66.42 | $787.7K | SEC ↗ |
| Feb 5, 2024 | Sharon Mates | Chairman, President & CEO | Sale | 33.9K | $67.07 | $2.3M | SEC ↗ |
| Feb 5, 2024 | Mark Neumann | EVP, Chief Commercial Officer | Sale | 11.9K | $67.15 | $796.4K | SEC ↗ |
| Feb 5, 2024 | Lawrence J. Hineline | SVP of Finance, CFO | Sale | 11.2K | $66.62 | $745.0K | SEC ↗ |
| Feb 5, 2024 | Suresh K. Durgam | EVP, Chief Medical Officer | Sale | 6.2K | $67.19 | $414.4K | SEC ↗ |
Showing the 25 most recent of 152 Form 4 filings for Intra-Cellular Therapies, Inc..
Most active ITCI insiders
- Sharon Mates29 filings
- Lawrence J. Hineline25 filings
- Michael Halstead23 filings
- Mark Neumann20 filings
- Suresh K. Durgam15 filings
Ask anything about ITCI insider activity
Use Trabud's AI agent to query Intra-Cellular Therapies, Inc.'s Form 4 history in plain English — "Show me ITCI CEO purchases this year" or compare it against any other ticker.
Open the AI agentITCI insider trading FAQ
Are Intra-Cellular Therapies, Inc. insiders buying or selling?
Intra-Cellular Therapies, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 152 Form 4 filings for ITCI: 11 buys ($11.5M) and 141 sells ($202.6M). Over the full record that is net selling of $191.0M.
How many insiders trade ITCI stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Intra-Cellular Therapies, Inc.. The most recent filing was accepted on Dec 6, 2024.
Where does Trabud get ITCI insider trading data?
All ITCI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.